Endocrine Weight Loss Study Guide 2026
Everything you need to pass the Endocrine Weight Loss exam in one place: the exam format, every topic to study, real practice questions with explanations, flashcards, and full-length practice tests. Free, no sign-up needed.
📚 Endocrine Weight Loss Topics to Study (33)
✍️ Sample Endocrine Weight Loss Questions & Answers
1. A man with hypogonadism (low testosterone) presents with increased body fat and loss of muscle mass. Testosterone replacement therapy is expected to:
Testosterone promotes muscle protein synthesis and lipolysis; replacing deficient testosterone in hypogonadal men reduces fat mass and increases lean mass.
2. Peptide YY (PYY) is released by L-cells in the distal gut in response to food intake and primarily acts to:
PYY is a satiety hormone that inhibits food intake by acting on hypothalamic Y2 receptors and slows gastric emptying to promote fullness.
3. Which receptor does naltrexone/bupropion (Contrave) target to reduce food reward and craving?
Naltrexone blocks opioid mu-receptors that normally inhibit POMC neurons, while bupropion inhibits dopamine/norepinephrine reuptake; together they suppress food reward and increase satiety.
4. A postmenopausal woman begins gaining significant abdominal weight despite no change in diet or activity. Her TSH is normal. Which hormonal change is the most likely contributing factor?
Loss of estrogen at menopause removes its suppressive effect on visceral fat accumulation, resulting in abdominal weight gain even without caloric changes, a hallmark of the menopausal body composition shift.
5. A patient with type 2 diabetes and obesity has elevated fasting insulin levels. This finding most directly indicates:
High fasting insulin in a hyperglycemic patient reflects compensatory pancreatic hypersecretion due to peripheral insulin resistance.
6. Which condition is associated with acanthosis nigricans (dark velvety skin in body folds) and strongly signals underlying insulin resistance?
Acanthosis nigricans is caused by insulin stimulating keratinocyte proliferation via IGF-1 receptors, making it a cutaneous marker of insulin resistance.